ARTEMIS (NCT06118281)

ARTEMIS – Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

PI: Stephanie Coulter, MD

Sponsor: Novo Nordisk

ACTIVE ENROLLING   SIGN UP

The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST elevation and non-ST-elevation myocardial infarction (MI).

Eligibility Requirements

1. Hospitalization for acute myocardial infarction with evidence of type 1 MI by invasive angiography performed at site with percutaneous coronary intervention (PCI) capabilities.

2. Presence of at least one of the following criteria confirmed based on the participant’s medical records and/or medical history interview:

• Any prior MI.
• Prior coronary revascularization.
• Diabetes mellitus treated with ongoing glucose-lowering agent(s).
• Known chronic kidney disease (eGFR ≥15 and <60 mL/min/1.73 m²).
• Prior ischemic stroke.
• Known carotid disease or peripheral artery disease in the lower extremities.
• Multivessel coronary artery disease (current/prior).

3. Age 18 years or above at the time of signing the informed consent.